Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma

Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma

Abstract Background Hyaluronic acid (HA) promotes cancer metastasis; however, the currently approved treatments do not target HA. Metastatic renal carcinoma (mRCC) is an incurable disease. Sorafenib (SF) is a modestly effective antiangiogenic drug for mRCC. Although only endothelial cells express kn...

Full description

Bibliographic Details
Main Authors: Jiaojiao Wang, Andre R. Jordan, Huabin Zhu, Sarrah L. Hasanali, Eric Thomas, Soum D. Lokeshwar, Daley S. Morera, Sung Alexander, Joseph McDaniels, Anuj Sharma, Karina Aguilar, Semih Sarcan, Tianyi Zhu, Mark S. Soloway, Martha K. Terris, Muthusamy Thangaraju, Luis E. Lopez, Vinata B. Lokeshwar
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Cancer Cell International
Subjects:
HAS3
Hyaluronic acid
4-methylumbelliferone
Renal cell carcinoma
Molecular targeting
Sorafenib
Online Access:https://doi.org/10.1186/s12935-022-02818-1

Internet

https://doi.org/10.1186/s12935-022-02818-1

Similar Items